Harpoon Therapeutics Inc
Change company Symbol lookup
Select an option...
HARP Harpoon Therapeutics Inc
VIRC Virco Mfg Corp
RVLP RVL Pharmaceuticals PLC
TRGP Targa Resources Corp
RCRT Recruiter.Com Group Inc
VGAS Verde Clean Fuels Inc
DHHC DiamondHead Holdings Corp
EJH E-Home Household Service Holdings Ltd
FLGC Flora Growth Corp
HL Hecla Mining Co
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. It is developing a pipeline of T cell engagers using its TriTACs, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN328, HPN217 and HPN536. The Company’s ProTriTAC product candidate include HPN601. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells.

Closing Price
$0.6725
Day's Change
-0.0145 (-2.11%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.6997
Day's Low
0.631
Volume
(Average)
Volume:
344,365

10-day average volume:
328,263
344,365

NEOGENOMICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NeoGenomics, Inc. - NEO

10:45 pm ET January 25, 2023 (Accesswire) Print

NEW ORLEANS, LA / ACCESSWIRE / January 25, 2023 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have untilFebruary 6, 2023 to file lead plaintiff applications in a securities class action lawsuit against NeoGenomics, Inc. (NasdaqCM:NEO), if they purchased the Company's securities between February 27, 2020 and April 26, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.

What You May Do

If you purchased securities of NeoGenomics and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-neo/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by February 6, 2023.

About the Lawsuit

NeoGenomics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On March 28, 2022, the Company disclosed that its CEO was stepping down effective immediately, that it expected 1Q2022 revenue and EBITDA below the low end of its prior guidance, and that it had withdrawn its 2022 annual financial guidance. On this news, shares of NeoGenomics fell $5.30 per share, or 29.8%. Then, on April 27, 2022, the Company disclosed its 1Q2022 financial results confirming revenue and EBITDA below its prior guidance, among other things, that the market "was moving towards larger, more comprehensive panels" and that the Company was "seeing bigger and bigger panels coming from…emerging companies . . . where we have not kept up." On this news, shares of NeoGenomics fell $0.41 per share, or 3.8%.

The case is Goldenberg v. NeoGenomics, Inc., No. 22-cv-10314.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. KSF serves a variety of clients - including public institutional investors, hedge funds, money managers and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC, Wednesday, January 25, 2023, Press release picture

CONTACT:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

lewis.kahn@ksfcounsel.com

1-877-515-1850

1100 Poydras St., Suite 3200

New Orleans, LA 70163

SOURCE: Kahn Swick & Foti, LLC





View source version on accesswire.com:

https://www.accesswire.com/736837/NEOGENOMICS-SHAREHOLDER-ALERT-BY-FORMER-LOUISIANA-ATTORNEY-GENERAL-KAHN-SWICK-FOTI-LLC-REMINDS-INVESTORS-WITH-LOSSES-IN-EXCESS-OF-100000-of-Lead-Plaintiff-Deadline-in-Class-Action-Lawsuit-Against-NeoGenomics-Inc--NEO



comtex tracking

COMTEX_423311413/2457/2023-01-25T22:45:58

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.